Program
BNT162 Vaccine
Also written as “BNT162b2”, “BNT162b1” and “BNT162b2 Vaccine”.
Its studies are mostly in COVID-19 · Influenza, Human · Pneumococcal Infections, led by 3 companies.
Drug pageBNT162 Vaccine: every studyAll 58 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNTechits history only | 202 open or running | phase 4since Oct 14, 2020 | Apr 27, 2020 | Apr 12, 2027phase 3 · NCT07798648 |
| Pfizerits history only | 20 open or running | phase 3since May 10, 2021 | May 10, 2021 | none ahead |
| PharmaJet | 11 open or running | phase 2since Apr 3, 2025 | Apr 3, 2025 | none ahead |
Also a collaborator on its studies: Fosun Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of PharmaJet only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 3, 2025First study: phase 2 study in Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy VolunteersFirst studyNCT06919796 · 40 planned · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
The one study PharmaJet leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06919796Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers · United States | 2 | Not yet recruiting | May 1, 2026 | 40 |
How it is read
Names in the registry
- “BNT162b2”, 16 entries
- “BNT162b1”, 3 entries
- “BNT162b2 Vaccine”, 2 entries
- “BNT162b2 (Omi XBB.1.5)”, 2 entries
- “BNT162b2 (2025/2026 formulation)”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 21 studies
- Influenza, Human, 1 study
- Pneumococcal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.